US Surgeons to Access the Smallest Fully Preloaded IOL Incision. RayOne™ Aspheric Receives FDA Clearance
Posted on 11/12/2018
Rayner, manufacturer of the world’s first IOL designed by Sir Harold Ridley, announced today that the US Food and Drugs Administration (FDA) have approved the RayOne™ Aspheric fully preloaded IOL injection system for use in the United States of America.
Product Approval Details
The FDA granted regulatory approval and sale of the RayOne™ Aspheric Monofocal (RAO600C), a fully preloaded aberration-neutral IOL covering a large power range of +8.0 D to +34.0 D.
About RayOne™ Aspheric
Lens and injector designed as one to create the smallest fully preloaded IOL incision
When creating the RayOne™ system, Rayner developed their new MICS lens and fully preloaded IOL injection system with patented Lock & Roll™ technology as part of the same design process. This combination has resulted in the smallest fully preloaded injector nozzle available – a 1.65 mm nozzle tip diameter for sub 2.2 mm delivery.
Lock & Roll™ technology rolls the lens to under half its size in one simple action, allowing the lens to pass smoothly though the fully enclosed cartridge, without the need for lens handling. This minimizes insertion force and enables a consistently smoother delivery.
Enhanced 6.0 mm optic, retaining proven stability and optical performance of existing platform
The new RayOne™ Aspheric MICS lens is an enhanced version of the tried-and-tested C-flex platform with an improved single 6.0 mm optic design. The material and design benefits of the original lens has been retained, without compromising on proven stability or optical performance.
What does this all mean for surgeons?
The RayOne™ Aspheric preloaded injector delivers the IOL consistently with expert control, through a micro incision with minimal wound stretch. RayOne™ Aspheric includes patented Lock & Roll™ technology for the smallest fully preloaded IOL incision.
Renewed Focus on the US
The FDA approval of RayOne™ Aspheric is the third in a pipeline of commercial and regulatory plans which Rayner will be executing over the next five years, a testament to Rayner’s commitment to transforming itself into one of the major players in the US market, all with the ambition of delivering better patient outcomes.
“We are delighted that the FDA has approved RayOne™ Aspheric for commercial distribution in the United States,” said James Crutchlow, Director of North America. “The approval completes what has been a transformative 12 months for Rayner in the United States, which began with the opening of the dedicated New York office and has since included FDA approvals for the 600C IOL and our new state-of-the-art manufacturing facility. To now bring our flagship RayOne™ Aspheric product to the world’s largest healthcare market and provide US healthcare professionals with the smallest fully preloaded incision is an ideal way to close 2018. We look forward to introducing this latest innovation in preloaded technology and building on the 600,000 OUS implantations of RayOne™ Aspheric.”